Clinical trials: Drug-Drug Interactions
Drug Interaction, GERD (Gastroesophageal Reflux Disease)
A Study to Investigate the Effect of Linaprazan Glurate on the Pharmacokinetics of Amoxicillin
This is an open, single arm, single-center Phase I trial designed to evaluate the effect of seven days repeated oral doses of linaprazan glurate on the pharmacokinetics (PK) of repeated doses of amoxicillin in healthy male and…
- Conditions
- Drug Interaction, GERD (Gastroesophageal Reflux Disease), Safety, and Tolerability
- Trial name
- NCT07308041
- Testing
- Drug Drug Interaction
- Where
- Sweden
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Cinclus Pharma Holding AB
Drug Interaction
Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates
This study is an open-label drug-drug interaction (DDI) study of ZYN002 transdermal gel and multiple drugs.
- Trial name
- NCT06930872
- Testing
- Part 1, Part 2
- Where
- Australia
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Harmony Biosciences Management, Inc.
Drug-drug Interaction Study
Drug-drug Interaction Study of Rifampin and Anaprazole Sodium
A drug-drug interaction study designed to evaluate the drug-drug interaction between rifampin capsules and anaprazole sodium enteric-coated tablets in healthy adult subjects
- Trial name
- NCT07330531
- Testing
- Anelazol Sodium Enteric-coated Tablets, Rifampicin Capsules
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Healthy, Drug Drug Interaction
Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects
Open-label, parallel, 2-arm, fixed-sequence study to investigate the effect of coadministration of a CYP3A4 inhibitor (Cohort 1, itraconazole multiple dose) and CYP3A4 inducer (Cohort 2, rifampin multiple dose) on the plasma PK…
- Trial name
- NCT04606537
- Testing
- Itraconazole, Rifampin, KBP-5074
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- KBP Biosciences
Drug Interaction
Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) Pharmacokinetics
The purpose of this study was to investigate how vamorolone affects the CYP3A4 enzyme in humans by measuring the pharmacokinetics of midazolam and its metabolite, 1'-hydroxymidazolam, in healthy subjects.
- Trial name
- NCT06689527
- Testing
- Vamorolone, Midazolam
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Santhera Pharmaceuticals
Drug Drug Interaction (DDI)
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
- Trial name
- NCT07265466
- Testing
- JP-1366 and clopidogrel, JP-1366 and aspirin, JP-1366 and atorvastatin
- Where
- South Korea
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Onconic Therapeutics Inc.
Drug Drug Interaction (DDI)
A Open-label, Drug-Drug Interaction With SB_MDZ in Healty Adult Subjects
This clinical trial is a phase 1, open-label, fixed-sequence, drug-drug interaction study to investigate the effect of single and multiple oral doses of SB17170 on the pharmacokinetics of SB_MDZ in healthy adult subjects.
- Trial name
- NCT06846684
- Testing
- SB17170, SB_MDZ
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- SPARK Biopharma
Drug-Drug Interaction Healthy Volunteers
Drug-Drug Interaction Between R1_PBK_M2301 and R2_PBK_M2301 in Healthy Adults
This is a Phase 1, open-label, randomized, crossover clinical trial designed to evaluate the potential drug-drug interaction (DDI) between R1_PBK_M2301 (levodropropizine 60 mg) and R2_PBK_M2301 (Pelargonium sidoides ethanol…
- Trial name
- NCT07017335
- Testing
- R1_PBK_M2301(Levocloperastine 60mg), R2_PBK_M2301 (Pelargonium sidoides extract)
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pharmbio Korea Co., Ltd.
RSV Infection, Drug Drug Interaction (DDI)
A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
The primary aim of the study is to assess the effect of itraconazole, carbamazepine, quinidine, and fluconazole individually on the pharmacokinetics and safety of EDP-323 in healthy adult participants.
- Trial name
- NCT06847464
- Testing
- EDP-323, Itraconazole, carbamazepine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
RSV Infection, Drug Drug Interaction
A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants
The primary aim of this study is to assess the effect of EDP-323 on the pharmacokinetics and safety of midazolam, caffeine, and rosuvastatin in healthy adult participants.
- Trial name
- NCT06917508
- Testing
- EDP-323, Midazolam, Caffeine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Pressure Injury, Fall Prevention
Clinical Investigation Evaluating the Use of NETSmart Solution , Incorporated to NETSoins Software, in the Care and Support of Elderly People Living in Nursing Homes
NETSmart software is designed to help doctors, nurses and care assistants adapt the care of elderly people living in nursing homes to the following risks: pressure injuries undernutrition interactions between different drugs…
- Conditions
- Pressure Injury, Fall Prevention, Undernutrition, Drug Interaction
- Trial name
- NETSMART DM (NCT07027358)
- Testing
- NETSmart software
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Teranga Software
Drug Drug Interaction
A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives
The goal of this clinical trial is to learn if drug aprocitentan has an effect on hormonal contraceptives in healthy female volunteers.
- Trial name
- NCT06799884
- Testing
- Ethinyl Estradiol / Levonorgestrel Oral Tablet, Aprocitentan
- Where
- Czechia
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Drug Drug Interaction (DDI)
A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates
The goal of this study is to learn if the investigational drug, BMS-984923 will impact the exposure and clearance of other medications when given together.
- Trial name
- NCT06632990
- Testing
- BMS-984923, Midazolam, Caffeine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Allyx Therapeutics
Drug Drug Interaction
Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3)
Primary objective: To evaluate the plasma and urine PK of Givinostat following multiple oral doses of Givinostat. Secondary objective: To assess the safety and tolerability multiple oral doses of Givinostat.
- Trial name
- NCT05860114
- Testing
- Givinostat
- Where
- Portugal
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Italfarmaco
Drug-Drug Interaction, Heathy Volunteer
Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity
Primary objective: 1. To assess the potential inhibitory and inducing effect of oral givinostat on the single dose pharmacokinetics (PK) of intravenous or oral midazolam. 2.
- Trial name
- NCT05492318
- Testing
- Givinostat 10 mg/mL, Midazolam 1mg/ml IV, Midazolam 2.5 mg oromucosal solution
- Where
- Portugal
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Italfarmaco
Safety Issues, Pharmacokinetics
Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam
This is a phase I, open-label, fixed sequence design, drug-drug-interaction (DDI) study divided in 2 parts. Part I is designed to evaluate whether concomitant treatment with linaprazan glurate and clarithromycin, a strong…
- Conditions
- Safety Issues, Pharmacokinetics, Drug Interaction, Tolerability
- Trial name
- NCT05633147
- Testing
- Linaprazan glurate, Drug drug interaction (DDI) - Clarithromycin (Part I), Drug drug interaction (DDI) - Midazolam (Part 2)
- Where
- Sweden
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Cinclus Pharma Holding AB
Drug Interaction
A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers
This is a single-centre, open-label, fixed-sequence trial to evaluate the impact of C21 on the exposure of CYP1A2, CYP2C9, CYP3A4 and P-gp substrates in healthy volunteers.
- Trial name
- NCT05830799
- Testing
- Drug Drug Interaction
- Where
- Sweden
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Vicore Pharma AB
Drug Drug Interaction
Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects
The drug-drug interaction study has been designed to investigate the effect of Fluvoxamine, Itraconazole and Paroxetine on the pharmacokinetics of ASN51
- Trial name
- NCT06232109
- Testing
- Fluvoxamine, Itraconazole, Paroxetine
- Where
- Netherlands
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Asceneuron S.A.
Drug Interaction
A Study to Evaluate Drug-drug Interaction of ZX-7101A Tablets and Oseltamivir Phosphate Capsules in Healthy Adult Subjects
The primary object of this study is evaluating the effect of multiple oral oseltamivir phosphate capsules on the pharmacokinetic profile of the active metabolite ZX-7101 after a single oral administration of ZX-7101A tablet in…
- Trial name
- ZX-7101A-208 (NCT06057103)
- Testing
- ZX-7101A, Oseltamivir, ZX-7101A and Oseltamivir
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Nanjing Zenshine Pharmaceuticals
Drug Interactions
Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects
This is a Phase 1, open-label, fixed-sequence, 2-part DDI study. Subjects will participate in only 1 study part.
- Trial name
- NCT05657613
- Testing
- CYP450 Cocktail and Transporter Substrates with Pacritinib, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- CTI BioPharma